Side effects are similar to those of buprenorphine and other opioids. In addition, naloxone can induce withdrawal symptoms in people who are addicted to opioids. The most common side effects (in order of most common to least common) of sublingual tablets include: headaches, opioid withdrawal syndrome, pain, nausea, increased sweating, and difficulty sleeping. The most common side effects seen in film formulations are tongue pain, decreased sensation and redness in the mouth, headache, nausea, vomiting, excessive sweating, constipation, signs and symptoms of opioid withdrawal, sleeping difficulties, pain, and swelling of the extremities.<unk>  has a milder side effect profile than methadone, and has limited respiratory effects, due to both agonist/antagonist effects. However,<unk>  may be less safe than methadone in people with stable liver disease, since it can elevate liver enzymes. Dependence and withdrawal<unk> , when taken in excess, can produce dysphoric symptoms for non opioid-dependent/tolerant individuals due to buprenorphine being a partial opioid agonist. The sublingual formulation of the<unk>  combination was designed to reduce the potential to inject the medication in comparison to buprenorphine alone. If the combination is taken via the sublingual route, as directed, the addition of naloxone does not diminish the effects of buprenorphine. When the combination sublingual tablet is dissolved and injected by opioid-dependent individuals, a withdrawal effect may be triggered due to the high parenteral bioavailability of naloxone. While this mechanism can potentially act to deter intravenous injection, the Suboxone formulation still has potential to produce an opioid agonist "high" if used sublingually by non-dependent persons, leading to dependence on opioids.
Buprenorphine/naloxone
Oxycodone/naloxone
Buprenorphine/naltrexone
Fentanyl/fluanisone
Buprenorphine/samidorphan
Dextromethorphan/quinidine
Naloxone
Nalorphine dinicotinate